Advanced

Recombinant activated factor VII: 30 years of research and innovation.

Hedner, Ulla LU (2015) In Blood Reviews 29. p.4-8
Abstract
Recombinant activated factor VII (rFVIIa) was initially developed to treat bleeding episodes in patients with congenital haemophilia and inhibitors. The story of its development began in the 1970s, when FVIIa was identified as one of the activated coagulation factors that has minimal potential for inducing thromboembolic side-effects. Extensive research over the last 30 years has greatly increased our knowledge of the characteristics of FVII, its activation, and the mechanisms by which rFVIIa restores haemostasis. In haemophilia, the haemostatic effect of rFVIIa is mediated via binding to thrombin-activated platelets at the site of injury, thereby enhancing thrombin generation also in the absence of factor (F) VIII or FIX. The mechanism of... (More)
Recombinant activated factor VII (rFVIIa) was initially developed to treat bleeding episodes in patients with congenital haemophilia and inhibitors. The story of its development began in the 1970s, when FVIIa was identified as one of the activated coagulation factors that has minimal potential for inducing thromboembolic side-effects. Extensive research over the last 30 years has greatly increased our knowledge of the characteristics of FVII, its activation, and the mechanisms by which rFVIIa restores haemostasis. In haemophilia, the haemostatic effect of rFVIIa is mediated via binding to thrombin-activated platelets at the site of injury, thereby enhancing thrombin generation also in the absence of factor (F) VIII or FIX. The mechanism of action of rFVIIa has also allowed its successful use in other clinical scenarios characterised by impaired thrombin generation, and its licensed uses have now been extended to acquired haemophilia, congenital FVII deficiency and Glanzmann's thrombasthenia. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood Reviews
volume
29
pages
4 - 8
publisher
Churchill Livingstone
external identifiers
  • pmid:26073368
  • wos:000357224800002
  • scopus:84931478113
ISSN
1532-1681
DOI
10.1016/S0268-960X(15)30002-3
language
English
LU publication?
yes
id
72fa17e1-5957-413f-a7c8-3262d639d15a (old id 7486341)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26073368?dopt=Abstract
date added to LUP
2015-07-08 15:18:24
date last changed
2017-11-19 03:12:20
@article{72fa17e1-5957-413f-a7c8-3262d639d15a,
  abstract     = {Recombinant activated factor VII (rFVIIa) was initially developed to treat bleeding episodes in patients with congenital haemophilia and inhibitors. The story of its development began in the 1970s, when FVIIa was identified as one of the activated coagulation factors that has minimal potential for inducing thromboembolic side-effects. Extensive research over the last 30 years has greatly increased our knowledge of the characteristics of FVII, its activation, and the mechanisms by which rFVIIa restores haemostasis. In haemophilia, the haemostatic effect of rFVIIa is mediated via binding to thrombin-activated platelets at the site of injury, thereby enhancing thrombin generation also in the absence of factor (F) VIII or FIX. The mechanism of action of rFVIIa has also allowed its successful use in other clinical scenarios characterised by impaired thrombin generation, and its licensed uses have now been extended to acquired haemophilia, congenital FVII deficiency and Glanzmann's thrombasthenia.},
  author       = {Hedner, Ulla},
  issn         = {1532-1681},
  language     = {eng},
  pages        = {4--8},
  publisher    = {Churchill Livingstone},
  series       = {Blood Reviews},
  title        = {Recombinant activated factor VII: 30 years of research and innovation.},
  url          = {http://dx.doi.org/10.1016/S0268-960X(15)30002-3},
  volume       = {29},
  year         = {2015},
}